Rachid Izzar Biogen Inc. (BIIB) insider trading activity

Rachid Izzar is Head of Global Product Strat. of BIOGEN INC.. Currently has a direct ownership of 9,701 shares of BIIB, which is worth approximately $1.69 Million. The most recent transaction as insider was on Feb 16, 2024, when has been sold 952 shares (Common Stock) at a price of $219.08 per share, resulting in proceeds of $208,564. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 9.7K

0% 3M change

57.89% 12M change

Total Value Held $1.69 Million

Rachid Izzar Transaction History

Date	Transaction	Value	Shares Traded	Shares Held
Feb 16 2024	SELL Payment of exercise price or tax liability	$208,564 $219.08 p/Share	952 Reduced 8.94%	9,701 Common Stock
Feb 16 2024	BUY Exercise of conversion of derivative security	-	2,017 Added 16.77%	10,014 Common Stock
Feb 09 2024	SELL Payment of exercise price or tax liability	$107,236 $240.98 p/Share	445 Reduced 4.9%	8,636 Common Stock
Feb 09 2024	BUY Exercise of conversion of derivative security	-	1,515 Added 14.3%	9,081 Common Stock
Feb 08 2024	SELL Payment of exercise price or tax liability	$149,226 $240.3 p/Share	621 Reduced 7.59%	7,566 Common Stock
Feb 08 2024	BUY Exercise of conversion of derivative security	-	2,043 Added 19.97%	8,187 Common Stock
Jun 30 2023	SELL Payment of exercise price or tax liability	$69,503 $284.85 p/Share	244 Reduced 3.82%	6,144 Common Stock
Jun 30 2023	BUY Exercise of conversion of derivative security	-	504 Added 7.31%	6,388 Common Stock
Feb 17 2023	SELL Payment of exercise price or tax liability	$103,278 $278.38 p/Share	371 Reduced 6.76%	5,117 Common Stock
Feb 17 2023	BUY Exercise of conversion of derivative security	-	767 Added 11.53%	5,884 Common Stock
Feb 10 2023	SELL Payment of exercise price or tax liability	$379,061 $286.3 p/Share	1,324 Reduced 19.44%	5,488 Common Stock
Feb 10 2023	BUY Exercise of conversion of derivative security	-	1,968 Added 23.66%	6,350 Common Stock
Jan 25 2023	BUY Grant, award, or other acquisition	-	1,783 Added 26.91%	4,844 Common Stock
Dec 02 2022	SELL Payment of exercise price or tax liability	$226,865 $298.9 p/Share	759 Reduced 19.87%	3,061 Common Stock
Dec 02 2022	BUY Exercise of conversion of derivative security	-	1,710 Added 34.48%	3,250 Common Stock
Jul 01 2022	SELL Payment of exercise price or tax liability	$31,173 $210.63 p/Share	148 Reduced 6.55%	2,110 Common Stock
Jul 01 2022	BUY Exercise of conversion of derivative security	-	504 Added 18.25%	2,258 Common Stock
Feb 18 2022	SELL Payment of exercise price or tax liability	$36,713 $209.79 p/Share	175 Reduced 9.07%	1,754 Common Stock
Feb 18 2022	BUY Exercise of conversion of derivative security	-	594 Added 23.54%	1,929 Common Stock
Feb 12 2022	SELL Payment of exercise price or tax liability	$26,180 $214.59 p/Share	122 Reduced 8.37%	1,335 Common Stock
Feb 12 2022	BUY Exercise of conversion of derivative security	-	351 Added 19.41%	1,457 Common Stock
Dec 02 2021	SELL Payment of exercise price or tax liability	$37,706 $228.52 p/Share	165 Reduced 12.98%	1,106 Common Stock
Dec 02 2021	BUY Exercise of conversion of derivative security	$85,009 $228.52 p/Share	372 Added 22.64%	1,271 Common Stock

Rachid Izzar

Head of Global Product Strat.

Cambridge, MA

Institutional Portfolio Updates

Receive a notification when an Institution or Guru buys or sells BIIB shares.

Notify only if

Value

Insider Trading

Get notified when an Biogen Inc. insider buys or sells BIIB shares.

Notify only if

Operation

Value

Type

News

Receive news related to BIOGEN INC.

Track Activities on BIIB

Account